ClinicalTrialsFinder
RecruitingNot ApplicableNCT07201194

Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

HOL-AKU: Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

Sponsor

Vejle Hospital

Enrollment

90 participants

Start Date

Nov 17, 2025

Study Type

INTERVENTIONAL

Conditions

Breast CancerColorectal, CancerProstate CancerLung CancerGynaecologic CancerPancreatic Cancer Metastatic

Summary

The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone. A total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone. The level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether holistic acupuncture can help reduce nausea in cancer patients who continue to feel nauseated during chemotherapy despite taking standard anti-nausea medications. Researchers want to see if this complementary approach can improve quality of life. **You may be eligible if...** - You are 18 or older - You are currently receiving chemotherapy and experiencing nausea despite anti-nausea drugs - Your chemotherapy is scheduled every 14 days with at least 2 more cycles planned - You understand and speak Danish **You may NOT be eligible if...** - You have brain metastases (cancer that has spread to the brain) - Your performance status is poor (greater than 2 on the ECOG scale) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHolistic acupuncture and acupressure

The intervention consists of one holistic and individualized consultation with an oncologist trained in acupuncture, in connection with outpatient chemotherapy. The consultation follows the principles of Traditional Chinese Medicine (TCM). The theoretical framework applied is Zang-Fu, which describes organ imbalances and aligns closely with Western medical understanding. Based on individual assessment and anamnesis, the patient receives acupuncture combined with acupressure. A maximum of 10 needles will be used, regardless of whether a deficiency or excess condition is identified. The acupuncture needles used are CAIR Super Silicon CSC-1, size 0.20 × 25 mm. The needles are inserted perpendicularly, except for Yin Tang, which is inserted transversely. The needles will remain in place for 25 minutes.

OTHERStandard medical treatment

Standard treatment and care includes chemotherapy, supportive antiemetic medication, close monitoring, and management of the patient's symptoms, side effects, and overall health.

Locations(1)

Department of Oncology, Vejle Hospital

Vejle, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07201194

Related Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

NCT072146624 locations

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT058799261238 locations

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT052868141 location

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693226 locations

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

NCT070504333 locations